CN Patent

CN119499394A — 亨廷顿（HTT）iRNA药剂组合物及其使用方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2025-02-25 · 1y expired

What this patent protects

本公开涉及靶向亨廷顿(HTT)基因(例如HTT基因的外显子1)的双链核糖核酸(dsRNAi)药剂和组合物，以及抑制HTT基因表达的方法和使用此类dsRNAi药剂和组合物治疗患有HTT相关疾病或病症(例如亨廷顿氏病)的受试者的方法。

USPTO Abstract

本公开涉及靶向亨廷顿(HTT)基因(例如HTT基因的外显子1)的双链核糖核酸(dsRNAi)药剂和组合物，以及抑制HTT基因表达的方法和使用此类dsRNAi药剂和组合物治疗患有HTT相关疾病或病症(例如亨廷顿氏病)的受试者的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN119499394A
Jurisdiction
CN
Classification
—
Expires
2025-02-25
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.